Allogeneic stem cell transplantation (allo-SCT) is a potentially curative therapy for chronic myeloid leukemia and Philadelphia chromosome-positive (Ph( þ )) acute lymphoblastic leukemia, and the graft-vs-leukemia (GVL) effect can eradicate residual leukemia after allo-SCT. Ph( þ ) leukemia cells frequently express death-inducing receptors (DR4 and DR5) for tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL), which is one of the cytotoxic ligands expressed on cytotoxic T cells and natural killer cells mediating the GVL effect. Here we demonstrate that imatinib specifically downregulated DR4 and DR5 expression in cell lines and clinical samples of Ph( þ ) leukemia. Second-generation tyrosine kinase inhibitors (dasatinib and nilotinib) and short hairpin RNA against bcr-abl also downregulated DR4 and DR5 expression in Ph( þ ) leukemia cells, and transfection of bcr-abl into a Ph( À ) leukemia cell line induced DR4 and DR5 expression, which was abrogated by imatinib treatment. Accordingly, Ph( þ ) leukemia cells that had been pretreated with imatinib showed resistance to the pro-apoptotic activity of recombinant human soluble TRAIL. These observations demonstrate that BCR-ABL is critically involved in the leukemia-specific expression of DR4 and DR5 and in the susceptibility of Ph( þ ) leukemia to TRAIL-mediated anti-leukemic activity, providing new insight into the mechanisms of the tumor-specific cytotoxic activities of TRAIL.
INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia chromosome (Ph), which results from a t(9;22) (q34;q11) chromosome translocation. [1] [2] [3] Approximately 20% 4 of adult and 5% 5 of childhood acute lymphoblastic leukemia (ALL) and 2% 2 of acute myeloblastic leukemia cases are also positive for Ph. The Ph carries the bcr-abl fusion gene, which encodes a chimeric protein termed BCR-ABL with upregulated tyrosine kinase activity, [1] [2] [3] that has a central role in the promotion of cell survival and proliferation of Ph( þ ) leukemia cells. Imatinib mesylate (Gleevec) (Druker et al. 6 ), an inhibitor of the kinase activity of BCR-ABL, became the standard therapy for all stages of CML 7 as well as Ph( þ ) ALL 8 and more potent second-generation tyrosine kinase inhibitors (TKIs), dasatinib and nilotinib, have also recently been approved by the health authorities. 2, 9, 10 Allogeneic stem cell transplantation (allo-SCT) is another therapy for the chronic phase of CML, as well as blastic crisis of CML (CML-BC) and Ph( þ ) ALL, 2, 11, 12 and is potentially curative. The graft-vs-leukemia (GVL) effect has a critical role in achieving a cure in patients with CML and Ph( þ ) ALL after allo-SCT. 2 The GVL effect is mediated by cytotoxic T lymphocytes and natural killer cells, 13, 14 and death receptor ligands including FasL and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have an important role in cytotoxic T-lymphocyte-and natural killer cell-mediated antitumor immunity. [15] [16] [17] [18] [19] [20] [21] [22] In bone marrow transplantation models using TRAIL-deficient mice, TRAIL was required for optimal graftvs-tumor activity, whereas it played little or no role in the development of graft-vs-host disease. 21 TRAIL triggers apoptosis of tumor cells by binding to its death domain-containing receptors, DR4 23 (TRAIL-R1) and DR5 24 (TRAIL-R2). We previously showed that Ph( þ ) leukemia cells frequently express DR4 and/or DR5 and are sensitive to the anti-leukemic activity of recombinant human soluble (rhs) TRAIL in contrast to their relative resistance to rhs FasL due to limited expression of Fas. 25 Accordingly, DR4 and DR5 expression on Ph( þ ) leukemias could mediate the GVL effect after allo-SCT at least in part.
Despite the importance of DR4 and DR5 expression on tumor cells for anti-tumor immunity, 26 there are very limited findings regarding the mechanisms for the expression of DR4 and DR5 on tumor cells. Considering the frequent expression of DR4 and DR5 on Ph( þ ) leukemias and resultant susceptibility to the antileukemic activity of rhs TRAIL, 25 it is feasible to predict that BCR-ABL itself may be involved in expression of DR4 and DR5 in Ph( þ ) leukemia cells. Our recent analysis on the effect of imatinib on TRAIL-resistant Ph( þ ) leukemia cells supports this assumption. 27 Thus, in the present study, we attempted to clarify the possible involvement of BCR-ABL in the expression of DR4 and DR5. We found that imatinib and short hairpin RNA (shRNA) against bcr-abl downregulated gene and cell surface expression of DR4 and DR5 in Ph( þ ) leukemia cells, whereas transfection of bcr-abl into a Ph( À ) leukemia cell line induced DR4 and DR5 expression. These observations demonstrate that BCR-ABL is critically involved in the Ph( þ ) leukemia-specific expression of DR4 and DR5.
RESULTS
TKIs downregulate DR4 and DR5 expression on Ph( þ ) leukemia cells We analyzed the effect of imatinib on cell surface expression of DR4 and DR5 in KOPM30, an imatinib-sensitive Ph( þ ) acute myeloblastic leukemia cell line expressing DR4 and DR5 but not (c-e) Viability and cell surface expression of DR4 and DR5 in imatinib-treated KOPM30 cells in the absence or presence of Q-VD-OPh. Cells cultured in the absence or presence of Q-VD-OPh (10 mM) with imatinib (0.5 mM) for 24 h were analyzed for the side scatter/forward scatter fraction and DR4 and DR5 expression by flow cytometry (c). Cell viability (d) and RFI of cell surface expression of DR4 and DR5 (e) are indicated with error bars (standard division) in triplicate experiments. (f and g) Gene expression of DR4 and DR5 in KOPM30 cells treated with TKIs. Cells cultured in the absence or presence of (f) imatinib (0.5 mM), (g) dasatinib (100 nM) or nilotinib (50 nM) for 12 and 24 h were analyzed for DR4 and DR5 gene expression by real-time reverse transcriptase PCR (RT-PCR) using GAPDH as an internal control. Relative gene expression levels are indicated with error bars in triplicate experiments. Asterisk indicates a significant difference (Po0.01, t-test) compared with time 0. (h) Cell surface expression of DR4 and DR5 in KOPM30 cells treated with dasatinib and nilotinib. Cells cultured in the absence or presence of dasatinib (100 nM) or nilotinib (50 nM) for 24 h were analyzed for DR4 and DR5 expression by flow cytometry. RFI is indicated. (i) Luciferase assay for promoter activities of the DR4 and DR5 genes in KOPM30 cells. Cells were transiently transfected with pGL3-basic, pGL3-DR4 or pGL3-DR5 reporter plasmids, and subsequently, 24 h after transfection, cultured in the absence or presence of imatinib (0.2 mM) for 24 h. Luciferase assay was performed using a cotransfected Renilla luciferase construct as a control for normalization of transfection efficiencies, and relative luciferase activity against pGL3-basic vector is indicated with error bars in triplicate experiments. the decoy receptors DcR1 and DcR2. 24, 28 Imatinib efficiently dephosphorylated tyrosine residues of BCR-ABL and also dephosphorylated downstream signaling molecules of BCR-ABL such as signal transducer and activator of transcription (STAT)5, mitogen-activated protein kinase (MAPK) and p70S6K at a concentration of as low as 0.125 mM (Figure 1a ). Of note, imatinib downregulated cell surface expression of DR4 and DR5 at a concentration of as low as 0.125 mM, but showed no effect on the DcR1 and DcR2 expression (Figure 1b) . To rule out the possibility that imatinib-induced cell death somehow downregulated DR4 and DR5 expression, we next monitored DR4 and DR5 expression on imatinib-treated KOPM30 cells in the presence or absence of Q-VD-OPh, a pan-caspase inhibitor. After 48 h incubation with imatinib, when assessed by side scatter/forward scatter, cell viability of KOPM30 was moderately decreased from 81 to 72% in the absence of Q-VD-OPh, and it was partially recovered to 76% in the presence of Q-VD-OPh (Figures 1c and d) . Although Q-VD-OPh itself weakly downregulated DR4 and DR5, imatinib-induced downregulation of DR4 and DR5 was not recovered in the presence of Q-VD-OPh (Figures 1c and e) , suggesting that induction of cell death was not the mechanism of DR4/DR5 downregulation by imatinib treatment. Consistent with the cell surface expression, imatinib downregulated gene expression of DR4 and DR5 (Figure 1c) . Not only imatinib but also dasatinib and nilotinib similarly downregulated gene (Figure 1d ) and cell surface (Figure 1e ) expression of DR4 and DR5. Finally, the luciferase assay demonstrated that imatinib downregulated DR4 and DR5 gene promoter activities (Figure 1f) .
We next analyzed the effect of imatinib on DR4 and DR5 expression on both Ph( þ ) (KOPN66bi and YAMN91) and Ph( À ) (Nalm6 and Reh) B-precursor ALL cell lines that expressed DR4 and/or DR5 at considerable levels. Imatinib (0.5 mM) efficiently downregulated DR4 and DR5 expression on KOPN66bi and YAMN91 (Figure 2a) , whereas it did not downregulate DR4 and DR5 expression on Nalm6 and Reh (Figure 2b ). We analyzed a total of 12 Ph( þ ) leukemia cell lines and confirmed that imatinib downregulated cell surface expression of DR4 and DR5 in all cell lines (Figure 2c ). Moreover, downregulation of gene expression of DR4 and DR5 by imatinib was documented in all seven Ph( þ ) leukemia cell lines tested (Figure 2d ). Finally, we analyzed the effect of imatinib on DR4 and DR5 expression in clinical samples from six Ph( þ ) ALL patients. Imatinib (0.5 mM) significantly downregulated cell surface expression of DR4 and DR5 in three and four out of six samples, respectively, and, as a whole, there was a statistically significant reduction in both DR4 and DR5 expression levels (Figure 2e ).
Inactivation of BCR-ABL specifically downregulates DR4 and DR5 expression on Ph( þ ) leukemia cells To verify the specificity of imatinib-induced DR4 and DR5 downregulation in Ph( þ ) leukemia cells, we tested an imatinibresistant Ph( þ ) leukemia cell line that carries a T315I mutation. SU-Ph2 is an imatinib-sensitive Ph( þ ) ALL cell line that expresses DR4 and DR5 and is sensitive to rhs TRAIL, whereas SU/SR is its imatinib-resistant subline having the T315I mutation ( Figure 3a ). 29 Imatinib effectively dephosphorylated BCR-ABL ( Figure 3a ) and downregulated gene ( Figure 3b ) and cell surface expression (Figure 3c ) of DR4 and DR5 in SU-Ph2, but much less so in SU/SR cells.
To further verify that inactivation of BCR-ABL downregulates DR4 and DR5 expression, we analyzed the effect of shRNA against bcr-abl. Using a lentivirus vector that contains green fluorescent protein (GFP) cDNA for cell sorting, we infected two sets of shRNAexpressing vector for bcr-abl (shRNA no. 
Introduction of BCR-ABL induces DR4/DR5 expression
As the above observations demonstrate that inactivation of BCR-ABL downregulates DR4 and DR5 expression in Ph( þ ) leukemia cells, we next tested if transfection of bcr-abl into Ph( À ) leukemia cells upregulates DR4 and DR5 expression using a BCR-ABLtransfected granulocyte/macrophage-colony stimulating factordependent TF1 cell line (Figure 4a ). In the presence of granulocyte/ macrophage-colony stimulating factor, gene expression of DR4 and DR5 was upregulated in the BCR-ABL-transfected cells compared with control TF1 cells, which was abrogated by imatinib treatment (Figure 4b ). Cell surface expression of DR4 and DR5 was also upregulated in the BCR-ABL-transfected cells, and the upregulated expression of DR5, but not DR4, returned to the control level by imatinib treatment (Figure 4c ). In the absence of granulocyte/macrophage-colony stimulating factor, basal gene expression of DR4 and DR5 was at a low level in control cells downregulated gene (Figure 5d ) and cell surface expression (Figure 5e ) of DR4 and DR5. To further verify the involvement of the MAPK pathway, short interfering RNA (siRNA) against ERK1 was introduced into KOPM30 cells using electroporation. Gene and protein expression of ERK1 were markedly lower by the introduction of siRNA against ERK1, but not by non-target siRNA (control), 30 and 36 h after transfection, respectively (Figures 5f  and g ). Gene and cell-surface expression of DR4 and DR5 were downregulated 36 h after transfection of siRNA against ERK1 (Figures 5f and h) . Next, to further verify the involvement of the BCR-ABL regulates TRAIL receptors in Ph þ leukemia I Kuroda et al PI3K pathway, the effects of two representative inhibitors of the PI3K pathway, wortmannin and AS605240, on DR4 and DR5 expression in KOPM30 cells were also tested. However, both wortmannin (up to 100 nM) and AS605249 (up to 10 mM) failed to downregulate cell surface expression of DR4 and DR5 (data not shown). These observations indicated that at least the MAPK pathway is involved in DR4 and DR5 expression in KOPM30 cells.
Imatinib impairs the anti-leukemic activity of TRAIL in Ph( þ ) leukemia cells Because imatinib downregulates cell surface expression of DR4 and DR5 in Ph( þ ) leukemia cells, it is assumed that the proapoptotic activity of TRAIL against Ph( þ ) leukemia cells may be functionally impaired by pretreatment with imatinib. Thus, we analyzed the effect of imatinib on the sensitivity of Ph( þ ) leukemia cells to rhs TRAIL under two conditions: (1) cells were pretreated with imatinib for 12 h and subsequently exposed to rhs TRAIL in the presence of imatinib for an additional 12 h and (2) cells were simultaneously exposed to rhs TRAIL and imatinib for 12 h. In KOPM30 cells, the pro-apoptotic activity of rhs TRAIL was highly impaired by pretreatment with imatinib (0.5 mM), while it was maintained by simultaneous treatment with imatinib ( Figures  6a and b) . Imatinib pretreatment impaired the pro-apoptotic activity of TRAIL at 0.125 mM (Figure 6c ), and reached a plateau at 0.25 mM that was maintained until 1.0 mM. In contrast, in KOPM28 cells, despite of its high sensitivity to the anti-leukemic activity of imatinib, 25 rhs TRAIL-induced cell death was rather enhanced by imatinib pretreatment (Figure 6b ) in a dose-dependent manner (Figure 6c ). To test the involvement of molecules that make up the death-inducing signaling complex and its downstream pathway in the different responses between KOPM28 and KOPM30, we performed Western blot analysis of these molecules in imatinibtreated KOPM28 and KOPM30 (Figure 6d ). In KOPM28, imatinib downregulated FLIP-S , an anti-apoptotic molecule as a negative regulator of caspase 8, but did not affect procaspase 8, FADD, FLIP-L , Bid, c-IAP1 and XIAP. In KOPM30, imatinib downregulated anti-apoptotic molecules such as FLIP-S , c-IAP1 and c-IAP2, and only upregulated anti-apoptotic FLIP-L . As summarized in Figure 6d , imatinib pretreatment at 0.5 mM significantly impaired sensitivity to the pro-apoptotic activity of rhs TRAIL in six out of the seven TRAIL-sensitive Ph( þ ) leukemia cell lines except for KOPM28. Of note, imatinib pretreatment of SU/SR cells, in which DR4 and DR5 expression was not downregulated due to the T315I mutation (Figure 3c ), 29 did not lead to impaired TRAIL sensitivity, whereas imatinib pretreatment of parental SU-Ph2 cells led to substantially impaired TRAIL sensitivity (Figure 6e ). We also tested the effect of imatinib pretreatment on the pro-apoptotic activity of rhs TRAIL using the primary sample from the Ph( þ ) ALL patient whose relative fluorescence intensity of DR4 and DR5 was downregulated from 4.0 and 4.5 to 2.0 and 2.5 by imatinib, respectively (Figure 2e) , and confirmed that pretreatment of the sample with imatinib significantly reduced the sensitivity to rhs TRAIL (% viability improved from 56.6±4.6 to 69.2±3.2%, P ¼ 0.0003 paired t-test) by trypan-blue exclusion assay (Figure 6f) .
DISCUSSION
In the present study, we showed that imatinib specifically downregulated DR4 and DR5 expression in cell lines and clinical samples of Ph1-positive leukemia. In addition to imatinib, not only second-generation TKIs, including dasatinib and nilotinib, but also shRNA against bcr-abl downregulated DR4 and DR5 expression in Ph( þ ) leukemia cells. Moreover, transfection of bcr-abl into a Ph( À ) leukemia cell line induced DR4 and DR5 expression that was abrogated by imatinib treatment. These observations clearly demonstrate that BCR-ABL has an important role in DR4 and DR5 expression in Ph( þ ) leukemia cells ( Figure 7 ). BCR-ABL promotes growth and survival of Ph( þ ) leukemia cells through activation of the MAPK, PI3K and JAK/STAT pathways that are usually under control of growth factor stimulation. 3 Among these signaling pathways, the present study demonstrated that at least the MAPK pathway is involved in BCR-ABL-mediated DR4 and DR5 expression. That an oncogenic fusion product derived from chromosomal translocation is implicated in DR4 and DR5 expression on leukemia cells is a unique finding and provides new insight into the mechanisms of the tumor-specific cytotoxic activities of TRAIL.
Because it has been reported that TRAIL has a role in innate immunity for immune surveillance against tumor development, [18] [19] [20] 22 our findings suggest that BCR-ABL sensitizes leukemia cells (or pre-leukemia cells) to innate immunity by upregulating DR4 and DR5 expression. This is a potentially paradoxical finding in that an oncogenic fusion protein indirectly suppresses expansion of leukemia cells. In this scenario, the chemical carcinogen methylcholanthrene (MCA)-induced mouse sarcoma model 20 may be worth noting: neutralization of endogenous TRAIL by anti-TRAIL antibody promoted development of sarcomas in mice treated with lowdose MCA but not significantly in mice treated with high-dose MCA. In this model, it was noted that high-dose MCA preferentially generated TRAIL-sensitive sarcomas, whereas low-dose MCA generated TRAIL-resistant sarcomas, suggesting that endogenous TRAIL-mediated immune surveillance could be overwhelmed by the emergence of high-potential tumors. 20 This experimental observation may be relevant to our paradoxical finding that Ph( þ ) leukemia cells show a clinically aggressive feature and poor therapeutic outcome upon chemotherapy despite of their sensitivity to TRAIL.
In addition to BCR-ABL, some other regulatory mechanisms also involve in DR4 and DR5 expression of Ph( þ ) leukemia cells. This assumption was supported by following two observations: (1) downreglation of DR4/DR5 expression by TKIs and siRNA against bcr-abl was partial in most of leukemia cell lines (e.c. KOPM28) and primary samples from Ph( þ ) ALL patients and (2) DR4 and DR5 expression was marginal in some Ph( þ ) leukemia cell lines (e.c. KOPN55bi) and primary samples from Ph( þ ) ALL patients. These mechanisms may include baseline activity of transcription factors and silencing by methylation of DR4 and DR5 gene promoter. 30 Thus, identification of these mechanisms that regulate DR4 and DR5 expression in Ph( þ ) leukemia cells cooperatively or independent with BCR-ABL is helpful to sensitize Ph( þ ) leukemia cells to pro-apoptotic activity of TRAIL. 27 In most of the Ph( þ ) leukemia cell lines, pretreatment with imatinib reduced their sensitivity to rhs TRAIL. In contrast, pretreatment of KOPM28 with imatinib moderately sensitized the cells to rhs TRAIL. Moreover, Nimmanapalli et al. 31 previously reported that cotreatment with imatinib and rhs TRAIL induced apoptosis of K562 cells. Although these findings were potentially contrary to each other, there are several aspects that need to be considered. First, in the previous report by Nimmanapalli et al.,
31
K562 cells were simultaneously treated with imatinib and rhs TRAIL. When cells were simultaneously treated with imatinib and rhs TRAIL in the present study, imatinib did not reduce sensitivity to rhs TRAIL, if not sensitized. Second, as discussed above, there were some residual expressions of DR4 and DR5 after imatinib treatment. In this aspect, residual cell surface expression level of DR5 on KOPM28 was still higher than the cell surface expression levels on most of the other untreated Ph( þ ) cell lines (Figure 2c ). Third, the effect of imatinib on death-inducing signaling complex and its downstream pathways must be considered. In fact, imatinib treatment of KOPM28 and KOPM30 induced some changes in expression of molecules involved in death-inducing signaling complex formation and its dowmnstream pathway (Figure 6d) . In KOPM30, most of those changes were downregulation of anti-apoptotic molecules such as FLIP-S , c-IAP1 and c-IAP2 except for upregulation of XIAP, suggesting that downregulation of DR4 and DR5 rather than changes in these molecules might be involved in the reduction of rhs TRAIL sensitivity. In KOPM28, the expression level of FLIP-L was relatively high and was downregulated by imatinib, suggesting that the combination of residual DR5 expression and FLIP-L downregulation might be involved in TRAIL sensitivity.
From the clinical point of view, our finding that in vitro pretreatment of Ph( þ ) leukemia cells with imatinib reduced their sensitivity to the pro-apoptotic activity of rhs TRAIL in most cell lines is potentially important. Because imatinib is now widely used for prophylaxis of relapse as well as controlling hematological relapse after allo-SCT, 12,32-34 our findings suggested the possibility that in some patients, but not in all patients, imatinib treatment might partially attenuate the in vivo activity of cytotoxic T lymphocytes and natural killer cells against Ph( þ ) leukemia cells that is mediated by the TRAIL/death receptor interaction. In this context, however, we also showed in vitro that, when Ph( þ ) leukemia cells were simultaneously treated with imatinib and rhs TRAIL, imatinib marginally impaired the pro-apoptotic activity of rhs TRAIL. Moreover, although downregulation of DR4 and DR5 expression by imatinib was observed in most of DR4/DR5-positive primary samples from Ph( þ ) ALL patients, attenuation of proapoptotic activity of rhs TRAIL was rather restrictive. These observations suggest that the risk of an attenuated GVL effect by imatinib after allo-SCT would be substantially minimal if any. Indeed, several clinical studies reported the benefit of combination of imatinb and donor lymphocyte infusion in treatment of relapsed CML and Ph( þ ) ALL patients after all-SCT. [35] [36] [37] Further in vivo studies are required to examine the effect of imatinib on TRAIL-mediated cellular immunity against Ph( þ ) leukemia.
MATERIALS AND METHODS

Leukemia cell lines
KOPM28, KOPM53, Nalm1, K562 and KOPN55bi were established from patients with CML-BC; KOPN57bi, KOPN66bi, KOPN72bi and YAMN91 from patients with Ph( þ ) ALL rearranged in minor bcr;
25 YAMN73 from a patient with Ph( þ ) ALL expressing the abl exon 2-spliced BCR-ABL (203 kd) protein; 38 and KOPM30 and KOPN30bi from the same patient at different stages of the disease rearranged in minor bcr.
25 SU-Ph2 is an imatinibsensitive cell line with double BCR-ABL fusion signals in fluorescence in situ hybridization analysis established from a patient with Ph( þ ) ALL, and SU/ SR is an imatinib-resistant subline of SU-Ph2 obtained after long-term culture with increasing concentrations of imatinib. 29 As Ph( À ) leukemia cell lines, Nalm6, a B-precursor ALL cell line, and Reh, a B-precursor ALL cell line with t(12;21), were used. All cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum.
Clinical samples
Leukemia cells were isolated from bone marrow or peripheral blood samples (blasts 490%) of six Ph( þ ) ALL patients. Two samples were obtained at diagnosis and four samples were obtained at relapse. All of the four relapsed patients had not been treated with imatinib before. Mononuclear cells separated by Ficoll-Hypaque density centrifugation were stored in liquid nitrogen and used for experiments. Patients' sample analysis was approved by the ethical review board of University of Yamanashi.
Reagents
Imatinib mesylate and nilotinib were kindly provided by Novartis Pharmaceuticals (Basel, Switzerland) and dissolved in dimethyl sulfoxide. Q-VD-OPh, SD1029, U0126 and LY294002 were purchased from Calbiochem (Darmstadt, Germany) and dissolved in dimethyl sulfoxide. Recombinant human interleukin-6 was kindly provided by Kyowa Hakko Kirin (Tokyo, Japan).
Western blot analysis
Cell lines were transferred to serum-free D-MEM/F12 medium and treated with different concentration of imatinib for 2 h. The harvested cells were treated with 1 mM of AEBSF, hydrochloric acid (4-(2-Aminoethyl) benzensulfonylfluoride, HCl) (Calbiochem) for 10 min on ice, and then solubilized Figure 6 . Effect of imatinib treatment on the pro-apoptotic activity of rhs TRAIL against Ph( þ ) leukemia cells. (a and b) Pro-apoptotic activity of rhs TRAIL on KOPM30 and KOPM28 pretreated with imatinib. Cells that have been pretreated with or without imatinib at 0.5 mM for 12 h were further incubated in the absence or presence of 100 ng/ml of rhs TRAIL for 12 h, or cells were cultured in the absence or presence of 100 ng/ml of rhs TRAIL with or without imatinib (0.5 mM) for 12 h. in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 0.05% NaN 3 , 1 mM phenylmethylsulfonyl fluoride and 100 mM sodium vanadate). The lysates were separated on a sodium dodecyl sulfatepolyacrylamide gel under reducing conditions and then transferred to a nitrocellulose membrane. The membrane was incubated with the first antibody at 4 1C overnight and then with horseradish peroxidase-labeled second antibody at room temperature for 1 h. The bands were developed using an enhanced chemiluminescence detection kit (Amersham Japan, Tokyo, Japan). As the first antibodies, anti-phospho-tyrosine monoclonal antibody (mAb) was purchased from Upstate Biotechnology (Lake Placid, NY, USA), anti-c-ABL mAb from Pharmingen (San Diego, CA, USA), anti-STAT5 mAb from Transduction Laboratories (Lexington, KY, USA), anti-p44/ 42 MAPK, anti-p70 S6 kinase (S6K), anti-phospho-STAT5 (Tyr694), antiphospho-p44/42 MAPK (Thr202/Tyr204) and anti-phospho-p70 S6K (Thr421/Ser424) rabbit sera from New England BioLabs (Beverly, MA, USA), anti-Bid rabbit serum from Cell Signaling Technology (Danvers, MA, USA), anti-c-IAP1 and anti-c-IAP2 Bid rabbit sera from R&D systems (Minneapolis, MN, USA), anti-caspase 8 mAb from MBL (Nagoya, Japan), anti-FLIP-S/L mAb from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-FADD and anti-XIAP mAbs from BD Biosciences (San Jose, CA, USA) and anti-b actin mAb from Sigma-Aldrich (St Louis, MO, USA). Horseradish peroxidase-conjugated anti-mouse IgG and anti-rabbit IgG were purchased from MBL.
Cell surface expression of TRAIL receptors mAbs specific for DR4 and DR5 were originally generated, and the specificity of each mAb was confirmed against baby hamster kidney cell lines stably transfected with respective human TRAIL receptors cDNAs as previously reported. 25 Cells (1 Â 10 6 cells) were incubated with 1 mg of biotinylated control mouse IgG1 or mAb on ice for 30 min. After washing, the cells were incubated with phycoerythrin-conjugated streptavidin (Biomeda, Foster City, CA, USA) on ice for 30 min and then analyzed by flow cytometry (FACSCalibur; BD Biosciences). The relative fluorescence intensity was calculated as the ratio of the mean fluorescence intensity of specific staining to that of control staining.
Real-time PCR analysis
Total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed with random hexamer (Amersham Bioscience, GE Healthcare Life Sciences, Little Chalfont, UK) and Superscript II reverse transcriptase (Invitrogen), and obtained cDNA was then incubated with 1 ml of RNase (Invitrogen) at 37 1C for 20 min. For quantitative real-time PCR of DR4, DR5 and ERK1 transcripts, triplicated samples containing 9 ml of cDNA with 10 ml of Taqman Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and 1 ml of 20 Â Assays-on-demand Gene Expression Product (DR4, Hs 00269492_m1; DR5, Hs 00366272_m1; ERK1, Hs 00385075_m1; Applied Biosystems) were preincubated at 50 1C for 2 min and subsequently at 95 1C for 10 min. Amplification was obtained by 40 cycles of reaction at 95 1C for 15 s and 60 1C for 1 min. Fluorescence data were quantitatively analyzed on ABI Prism 7500 Sequence Detection System (Applied Biosystems). Nalm1 was used for positive control. As an internal control, quantitative real-time PCR for GAPDH (Hs 99999905_m1; Applied Biosystems) was performed.
Cytotoxic activity assays
Rhs TRAIL (Killer TRAIL), which is composed of the extracellular domain of human TRAIL fused at the N-terminus to a linker peptide and His-tag was purchased from Alexis Biochemicals (San Diego, CA, USA). To detect the early apoptotic event, cells (4 Â 10 5 cells/ml) were cultured in the absence or presence of rhs TRAIL (100 ng/ml), harvested at 12 h, stained with fluorescein isothiocyanate-conjugated annexin V (MBL) and propidium iodide and analyzed by flow cytometry (FACSCalibur). For clinical sample, trypan-blue exclusion assay was performed.
Reporter assays A À 820/ À 2 fragment of the DR4 gene generated using PCR was cloned into the pGL3-basic vector (Promega, Madison, WI, USA) and subjected to nucleotide sequence analysis. 30 The Pst/MluI fragment of the DR5 gene cloned into the pGL3-basic vector was a gift from T Sakai (Kyoto Prefectural University of Medicine, Japan). 39 pRL-TK vector (Promega) was used to monitor the transfection efficiency. Transfection was performed in triplicate by lipofectamine (Invitrogen) following the manufacturer's instruction. After 24 h transfection, aliquots of cells were cultured in the presence or absence of 0.2 mM of imatinib for 24 h, and the cells were finally harvested for assay 48 h after transfection. Activities of firefly and Renilla luciferases were measured sequentially using Dual-Luciferase reporter assay system (Promega).
Lentivirus shRNA/siRNA expression vectors and infection pLL3.7 lentiviral vector was engineered to produce shRNAs under the control of mouse U6 promoter and co-express GFP as a reporter gene by CMV-GFP expression cassette. 40 siRNA-target sequences were designed to be homologous to the p190 bcr-abl cDNA sequence, and oligonucleotides were subcloned into pLL3.7. The selected sequences were submitted to BLAST search to assure that only bcr-abl was targeted. Among five sets of oligonucleotides containing siRNA-target sequences, the following two sets were selected for further analysis due to the specificity and efficiency: no. 1, 5
0 -TgggtcttaggctataatcaTTCAAGAGAtgattatagcctaagacccTTTTTTC-3 0 (blunt-siRNA/sense hairpin-siRNA/antisense-polyA-XhoI/forward); no. 3, 5 0 -TgattccatccagcaaatgaTTCAAGAGAtcatttgctggatggaatcTTTTTTC-3 0 (forward). The control vector contained the following ineffective sequence: 5 0 -TgcaatattacatatacgccTTCAAGAGAggcgtatatgtaatattgcTTTTTTC-3 0 (forward). pLL3.7 shRNA vector or control vector was cotransfected with packaging vector into 293FT cells and the resulting supernatant was collected after 36 h. 41 Lentivirus was recovered after ultracentrifugation and infected to KOPM30 cells.
Introduction of siRNA using electroporation siRNA against ERK1 (s230180) and non-specific siRNA were purchased from Applied Biosystems. Introduction of siRNA into KOPM30 cells was performed using Neon Transfection System (Life Technologies, Carlsbad, CA, USA). Electroshock (pulse voltage, 1700 V; pulse width, 20 ms; pulse number, Â 1) was performed using T-buffer, and cells were harvested for real-time reverse transcriptase PCR and immunoblotting or flow cytometric analysis 30 and 36 h after electroporation, respectively.
